Resources from the same session
993MO - A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
Presenter: Chongren Wang
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
994MO - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
995MO - Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade
Presenter: Adam Grippin
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant 993MO, 994MO and 995MO
Presenter: Akseli Hemminki
Session: Mini oral session: Investigational immunotherapy
Resources:
Slides
Webcast
996MO - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation
Presenter: Jason Luke
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
997MO - A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01
Presenter: Joanne Lundy
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
998MO - Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study
Presenter: Oliver Klein
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant 996MO, 997MO and 998MO
Presenter: John Haanen
Session: Mini oral session: Investigational immunotherapy
Resources:
Slides
Webcast
999MO - HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma
Presenter: Christian Ottensmeier
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1000MO - A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors
Presenter: Kristopher Wentzel
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast